By Research and Markets (http://www.researchandmarkets.com/research/3jdw4p/primary_biliary) has announced the addition of the "Primary Biliary Cirrhosis - Pipeline Review, H2 2013" report to their offering.
'Primary Biliary Cirrhosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Primary Biliary Cirrhosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Primary Biliary Cirrhosis.
Scope
- A snapshot of the global therapeutic scenario for Primary Biliary Cirrhosis.
- A review of the Primary Biliary Cirrhosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Primary Biliary Cirrhosis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Companies Mentioned
- Johnson & Johnson
- GlaxoSmithKline plc
- AlbireoPharma
- NovImmune SA
- Intercept Pharmaceuticals, Inc.
- Dr. Falk Pharma GmbH
- Lumena Pharmaceuticals, Inc.
Drug Profiles
- budesonide
- obeticholic acid
- NI-0801
- ustekinumab
- LUM-001
- Umbilical Cord Mesenchymal Stem Cell Transplantation
- obeticholic acid
- GSK-2330672
- Mesenchymal Stem Cells
- A-4250
For more information visit http://www.researchandmarkets.com/research/3jdw4p/primary_biliary
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals
